appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Biocon Ltd
BIOCON
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Biocon Limited is a biopharmaceutical company engaged in the research & development and manufacture of pharmaceuticals, medicinal chemical and botanical products.
Brands
Brands
PeersCompare with peers
Hester Biosciences Ltd
Panacea Biotec Ltd
Zenotech Laboratories Ltd
Transgene Biotek Ltd
Vivo Bio Tech Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Hmm, looks like data is unavailable here. Please come back after some timeRecent EventsAll events
Board Meeting Intimation
BIOCON LIMITED has informed the Exchange about Board Meeting to be held on 30-Oct-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2024 . | Download
BIOCON LIMITED has informed the Exchange about Board Meeting to be held on 30-Oct-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2024 . | Download
Press Release
Biocon Limited has informed the Exchange regarding a press release dated October 03, 2024, titled "Biocon Biologics Refinances USD 1.1 Billion (INR 93,468 million) Long Term Debt through USD Bonds and New Syndicated Facility". | Download
Biocon Limited has informed the Exchange regarding a press release dated October 03, 2024, titled "Biocon Biologics Refinances USD 1.1 Billion (INR 93,468 million) Long Term Debt through USD Bonds and New Syndicated Facility". | Download
Cash Dividend
Final • Div/Share: ₹ 0.5
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant